

FIG. 1

Sequence of human APRIL (SEQ ID NOS: 1 and 2)

Human G70 cDNA (SEQ ID NO 1)

Length: 1465 bp

```

1  GCCAACCTTC CCTCCCCCAA CCCTGGGGGCC GCCCCAGGGT TCCTGCGCAC
51  TGCCTGTTCC TCCTGGGTGT CACTGGCAGC CCTGTCCTTC CTAGAGGGAC
101 TGGAACCTAA TTCTCCTGAG GCTGAGGGAG GGTGGAGGGT CTCAAGGCAA
151 CGCTGGCCCC ACGACGGAGT GCCAGGAGCA CTAACAGTAC CCTTAGCTTG
201 CTTTCCTCCT CCCTCCTTTT TATTTTCAAG TTCCTTTTTA TTTCTCCTTG
251 CGTAACAACC TTCTTCCCTT CTGCACCACT GCCCGTACCC TTACCCGCCC
301 CGCCACCTCC TTGCTACCCC ACTCTTGAAA CCACAGCTGT TGGCAGGGTC
351 CCCAGCTCAT GCCAGCCTCA TCTCCTTTCT TGCTAGCCCC CAAAGGGCCT
401 CCAGGCAACA TGGGGGGGCC AGTCAGAGAG CCGGCACTCT CAGTTGCCCT
451 CTGGTTGAGT TGGGGGGCAG CTCTGGGGGC CGTGGCTTGT GCCATGGCTC
501 TGCTGACCCA ACAAACAGAG CTGCAGAGCC TCAGGAGAGA GGTGAGCCGG
551 CTGCAGGGGA CAGGAGGCCC CTCCCAGAAT GGGGAAGGGT ATCCCTGGCA
601 GAGTCTCCCG GAGCAGAGTT CCGATGCCCT GGAAGCCTGG GAGAGTGGGG
651 AGAGATCCCG GAAAAGGAGA GCAGTGCTCA CCCAAAACA GAAGAAGCAG
701 CACTCTGTCC TGCACCTGGT TCCCATTAAAC GCCACCTCCA AGGATGACTC
751 CGATGTGACA GAGGTGATGT GGCAACCAGC TCTTAGGCGT GGGAGAGGCC
801 TACAGGCCCA AGGATATGGT GTCCGAATCC AGGATGCTGG AGTTTATCTG
851 CTGTATAGCC AGGTCCTGTT TCAAGACGTG ACTTTCACCA TGGGTCAGGT
901 GGTGTCTCGA GAAGGCCAAG GAAGGCAGGA GACTCTATTC CGATGTATAA
951 GAAGTATGCC CTCCCACCCG GACCGGGCCT ACAACAGCTG CTATAGCGCA
1001 GGTGTCTTCC ATTTACACCA AGGGGATATT CTGAGTGTC TAATTCCCCG
1051 GGCAAGGGCG AAACCTTAACC TCTCTCCACA TGGAACCTTC CTGGGGTTTG
1101 TGAAACTGTG ATTGTTGTTAT AAAAAGTGGC TCCCAGCTTG GAAGACCAGG
1151 GTGGGTACAT ACTGGAGACA GCCAAGAGCT GAGTATATAA AGGAGAGGGA
1201 ATGTGCAGGA ACAGAGGCGT CTTCCTGGGT TTGGCTCCCC GTTCCTCACT
1251 TTTCCCTTTT CATTCCCACC CCCTAGACTT TGATTTTACG GATATCTTGC
1301 TTCTGTTCCC CATGGAGCTC CGAATTCTTG CGTGTGTGTA GATGAGGGGC
1351 GGGGGACGGG CGCCAGGCAT TGTTCAAGACC TGGTCGGGGC CCACTGGAAG
1401 CATCCAGAAC AGCACCACCA TCTAACGGCC GCTCGAGGGA AGCACCCGGC
1451 GGT TTGGGCG AAGTC

```

The proposed transmembrane domains are boxed

human G70 protein sequence (SEQ ID NO 2)

```

1  MPASSPFLLA PKGPPGNMGG PVREPALSA LWLSWGAALG AVACAMALLT
51  QQTELQSLRR EVSRLQGTGG PSQNGEGYPW QSLPEQSSDA LEAWESGERS
101 RKRRAVLTQK QKKQHSVLHL VPINATSKDD SDVTEVMWQP ALRRGRGLQA
151 QGYGVRIQDA GYLLYSQVL FQDVTFTMGQ VVSREGQGRQ ETLFR CIRSM
201 PSHPDRA YNS CYSAGVFHLH QGDILSVIIP RARAKLNLSP HGTF LGFV

```

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 2A

Sequence of mouse G70 (SEQ ID NOS: 3 and 4)

Mouse G70 (SEQ ID NO 3)

1	CATGCCGAGT	GCTTTGTGTG	TGTTACCTGC	TCTAAGAAGC	TGGCTGGGCA
51	GCGTTTCACC	GCTGTGGAGG	ACCAGTATTA	CTGCGTGGAT	TGCTACAAGA
101	ACTTTGTGGC	CAAGAAGTGT	GCTGGATGCA	AGAACCCCAT	CACTGGGTTT
151	GGTAAAGGCT	CCAGTGTGGT	GGCCTATGAA	GGACAATCCT	GGCACGACTA
201	CTGCTTCCAC	TGCAAAAAAT	GCTCCGTGAA	TCTGGCCAAC	AAGCGCTTTG
251	TATTTCATAA	TGAGCAGGTG	TATTGCCCTG	ACTGTGCCAA	AAAGCTGTAA
301	CTTGACGGCT	GCCCTGTCCT	TCCTAGATAA	TGGCACCAAA	TTCTCCTGAG
351	GCTAGGGGGG	AAGGAGTGTC	AGAGTGTAC	TAGCTCGACC	CTGGGGACAA
401	GGGGGACTAA	TAGTACCCTA	GCTTGATTTC	TTCTATTCT	CAAGTTCCTT
451	TTTATTTCTC	CCTTGCGTAA	CCGCTCTTC	CCTTCTGTGC	CTTTGCCTGT
501	ATTCCCACCC	TCCCTGCTAC	CTCTTGGCCA	CCTCACTTCT	GAGACCACAG
551	CTGTTGGCAG	GGTCCCTAGC	TCATGCCAGC	CTCATCTCCA	GGCCACATGG
601	GGGGCTCAGT	CAGAGAGCCA	GCCCTTTCGG	TTGCTCTTTG	GTTGAGTTGG
651	GGGGCAGTTC	TGGGGGCTGT	GA ⁺ CTTGTGCT	GTCGCACTAC	TGATCCAACA
701	GACAGAGCTG	CAAAGCCTAA	GGCGGGAGGT	GAGCCGGCTG	CAGCGGAGTG
751	GAGGGCCTTC	CCAGAAGCAG	GGAGAGCGCC	CATGGCAGAG	CCTCTGGGAG
801	CAGAGTCCTG	ATGTCCTGGA	AGCCTGGAAG	GATGGGGCGA	AATCTCGGAG
851	AAGGAGAGCA	GTA ⁺ CTACCC	AGAAGCACAA	GAAGAAGCAC	TCAGTCCTGC
901	ATCTTGTTCC	AGTTAACATT	ACCTCCAAGG	ACTCTGACGT	GACAGAGGTG
951	ATGTGGCAAC	CAGTACTTAG	GCGTGGGAGA	GGCCTGGAGG	CCCAGGGAGA
1001	CATTGTACGA	GTCTGGGACA	CTGGAATTTA	TCTGCTCTAT	AGTCAGGTCC
1051	TGTTTCATGA	TGTGACTTTC	ACAATGGGTC	AGGTGGTATC	TCGGGAAGGA
1101	CAAGGGAGAA	GAGAAACTCT	ATTCCGATGT	ATCAGAAGTA	TGCCTTCTGA
1151	TCCTGACCGT	GCCTACAATA	GCTGCTACAG	TGCAGGTGTC	TTTCATTTAC
1201	ATCAAGGGGA	TATTATCACT	GTCAAAATTC	CACGGGCAA	CGCAAAACTT
1251	AGCCTTTCTC	CGCATGGAAC	ATTCCTGGGG	TTTGTGAAAC	TATGATTGTT
1301	ATAAAGGGGG	TGGGGATTTC	CCATTCCAAA	AACTGGCTAG	ACAAAGGACA
1351	AGGAACGGTC	AAGAACAGCT	CTCCATGGCT	TTGCCTTGAC	TGTTGTTTCT
1401	CCCTTTGCCT	TTCCCGCTCC	CACTATCTGG	GCTTTGACTC	CATGGATATT
1451	AAAAAAGTAG	AATATTTTGT	GTTTATCTCC	CAAAAA	

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SERIAL NO.: 09/854,864
 INVENTORS: Theill, et al.
 Page 3 of 49



FIG. 2B

Mouse G70 Length: 241 (SEQ ID NO 4)

```

1  MPASSPGHMG GSVREPALSV ALWLSWGAVL GAVTCAVALL IQQTELQSLR
51  REVSRLQRSQ GPSQKQGERP WQSLWEQSPD VLEAWKDGAQ SRRRRAVLTQ
101 KHKKKHSLVH LVPVNITSKD SDVTEVMWQP VLRRGRGLEA QGDIVRVWDT
151 GIYLLYSQVL FHDVTFTMGQ VVSREGQGRR ETLFRCIRSM PSDPDRAVNS
201 CYSAGVFHLH QGDIITVKIP RANAKLSLSP HGTFLGFVKL *
```


G-70 FLAG des92 (smuG70) Strain #4081 (SEQ ID NO 19):

```


MDYKDDDDKKKKKKHSLVHLPVNITSKDSQDVTEVMWQPVLRGRGLEAQGDIVRVWDTGIY
LLYSQVLFDHVTFTMGQVVSREGQGRRETLEFRCIRSMPSDPDRAYNSCYSAGVFHLHQDII
TVKIPRANAKLSLSPHGTFLGFVKL*
```


FIG. 4A


Effect of sG70/April on Raji cell proliferation



Effect of sG70/April on Jurkat cell proliferation




Effect of sG70/April on K562 cell proliferation




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 4B


Effect of sG70/April on U937 cell proliferation




Effect of sG70/April on 293 T cell proliferation



Effect of sG70/April on 3T3 cell proliferation





APPROVED	O.C. FIG.	
EY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 5B-1





FIG. 5B-2



APPROVED	FIG. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SERIAL NO.: 09/854,864
 INVENTORS: Theill, et al.
 Page 9 of 49



43463 498566

FIG. 5B-3








FIG. 6

The effect of r-G70/April on human peripheral blood B cell, T cell and Granulocyte



The effect of IL-2 and G70/April on human peripheral T cell proliferation




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		




FIG. 7

Effect of sG70/April on murine B cell proliferation



Effect of sG70/April on murine T cell proliferation



494566

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 8

Effect of G70/April on murine T cell
proliferation costimulated through CD28
antibody






FIG. 9

Co-stimulatory activity of G70/April on mouse T cells






FIG. 11

Alignment of human BCMA amino acid sequence and murine BCMA amino acid sequence

murine BCMA amino acid sequence Length: 185 (SEQ ID NO: 11):

1 MAQQCFHSEY FDSLLHACKP CHLRCSNPPA TCQPYCDPSV TSSVKGTYTV
51 LWIFLGLTLV LSLALFTISF LLRKMNPEAL KDEPQSPGQL DGSAQLDKAD
101 TELTRIRAGD DRIFPRSLEY TVEECTCEDC VKSKPKGDS D HFFPLPAMEE
151 GATILVTTKT GDYKSSVPT ALQSVGMGEK PTHTR

alignment of human BCMA amino acid sequence and murine BCMA amino acid sequence.

Query: 4 MAGQCSQNEYFDSLLHACIPCQLRCSNTPFLTCQRYCNASVTNSVKGTNAILWTCGLS 63
MA QC +EYFDSLLHAC PC LRCS+ PP TCQ YC+ SVT+SVKGT +LW LGL+
Sbjct: 1 MAQQCFHSEYFDSLLHACKPCHLRCSN--PPATCQPYCDPSVTSSVKGTYTVLWIFLGLT 58

Query: 64 LIISLAVFVLMFLLRKISSEPLKDEFKNTG----SGLLGMANIDLEKSRTGDEIILPRGL 119
L++SLA+F + FLLRK++ E LKDE ++ G S L A+ +L + R GD+ I PR L
Sbjct: 59 LVLSLALFTISFLLRKMNPEALKDEPQSPGQLDGSAQLDKADTELTRIRAGDDRIFFRSL 118

Query: 120 EYTVEECTCEDCIKSKPKVDSHDHCFPLPAMEEGATILVTTKTNDYCKS-LPAAL-SATEI 177
EYTVEECTCEDC+KSKPK DSDH FPLPAMEEGATILVTTKT DY KS +P AL S +
Sbjct: 119 EYTVEECTCEDCVKSKPKGDS DHFFPLPAMEEGATILVTTKTGDYKSSVPTALQSVGMG 178

Query: 178 EKSISAR 184
EK R
Sbjct: 179 EKPTHTR 185

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 13

Alignment of cysteine rich extracellular regions of human TACI and human BCMA.

```

34 CPEEQYWDPLLGTCSCKTICNHQS.QRTCAAFCSRSLSCRKEQGKFYDHL 82
   | : :|. | || |. |. |. . || :| . . | . :
8  CSQNEYFDSLLHACIPCQLRCSSNTPPLTCQRYCNASVTNSVKGT..NAI 55

      .
83 LRDCISCASI 92
   | | : . |
56 LWTCLGLSLI 65
  
```

4904566

APPROVED	FIG. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 14A





FIG. 14B




APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

SERIAL NO.: 09/854,864
INVENTORS: Theill, et al.
Page 21 of 49



FIG. 14C



APPROVED	D.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

FIG. 15A




FIG. 15B






FIG. 16A





FIG. 16B






FIG. 16C




FIG. 16D

49463494550



FIG. 17A




FIG. 17B







FIG. 17C



[illegible]

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 19A




FIG. 19B




FIG. 20A




FIG. 20B





FIG. 20C



APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



Fc-humanAPRIL protein sequence including the signal sequence, Fc domain, linker (XhoI site) and APRIL:

FIG. 21

Fc-humanAPRIL

```
1  MEWSWVFLFF LSVTTGVHSD KTHTCPPCPA PELLGGPSVF
   LFPPKPKDTL
51  MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP
   REEQYNSTYR
101 VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG
   QPREPQVYTL
151 PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNQQPENNY
   KTTPPVLDSD
201 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL
   SLSPGK SRAV
251 LTQKQKKQHS VLHLVPINAT SKDDSDVTEV MWQPALRRGR
   GLQAQGYGVR
301 IQDAGVYLLY SQVLFQDVTF TMGQVVSREG QGRQETLERC
   IRSMPSHPDR
351 AYNCSYSAGV FHLHQGDILS VIIPRARA KL NLSPHGTF LG
   FVKL*
```





FIG. 22
 Fc-HumanAPRIL and soluble human AGP3
 stimulate proliferation of primary B cells



09/854,864

FIG. 23

hBCMA-Fc and wt hTACI-Fc inhibits
 Flag-mAPRIL mediated mouse B cell
 proliferation






FIG. 24

hBCMA-Fc reduces PB B cell level *in vivo*

15 mg/kg ip on day 0, 3, and 6

BLOOD		WBC	#Lym	CD3+	CD3-B220+
		10e6/ml	10e6/ml	#	#
BCMA-Fc		5.30	3.81	2.3	1.3
	SD	0.39	0.43	0.32	0.27
	t test	0.03318	0.01570	0.24737	0.00506
Fc		8.02	6.43	2.7	3.2
	SD	1.27	1.52	0.6	0.6
Saline		6.90	5.55	2.1	2.9
	SD	2.04	1.79	0.5	1.2



FIG. 25

hBCMA-Fc reduces spleen B cell levels *in vivo*
15 mg/kg ip on day 0, 3, and 6

Spleen	WBC 10e6/ml	Lym (%)	spleen lym# 10ml(x10e6)	CD3-B220+ (%)	CD3-B220+ #
BCMA-Fc SD t test	9.12	97.9	89.3	45.5	41.8
	0.92	0.51	9.32	1.29	4.92
	0.02778	0.89118	0.02668	0.00234	0.02088
Fc SD	11.49	97.9	112.5	50.6	57.1
	1.62	0.38	15.65	1.95	9.67
Saline SD	11.48	98.5	113.1	53.7	48.5
	1.71	0.1	16.9	6.7	29.15



FIG. 26

Flag-mAPRIL and hAGP3 mediated IgA production
 inhibited by hBCMA-Fc and hTACI-Fc *in vitro*







FIG. 27

Flag-mAPRIL and hAGP3 Mediated IgG Production
 Inhibited by BCMA-Fc and TACI-Fc *in Vitro*







FIG. 28

Significantly reduces total IgE and IgA in normal mice treated with mBCMA-Fc and trun hTACI-Fc 5 mg/kg ip day 0, 3, and 6




FIG. 29

BCMA-Fc and truncated TACI-Fc at daily doses of 0.5 mg/kg inhibits humoral immunity *in vivo*







FIG. 30

Anti-mAPRIL c-19 MAb
 Inhibition of APRIL mediated B cell proliferation




44463 434369

APPROVED	U.C. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 31
Neutralizing anti-mAPRIL Mab Reduces anti-Pneumovax IgM *In Vivo*
5 mg/kg ip on day 0, 3, and 6




^a difference between Anti-April Ab and anti-AGP3 Pb Peak 2 + Anti-April Ab Groups



FIG. 32

Effect of hBCMA-Fc in NCB/NCWF1 mice
 Survival graph from various treatment groups




N=10 Mice were treated for 8 weeks 3x/week with the indicated proteins. KIN2 group had 12 mice.
 The 100 in the legend stands for 100 µg of protein or 4mg/kg i.p.



FIG. 33

Effect of hBCMA-Fc in NCB/NCWF1 mice
 Percentage of mice with proteinuria (>300mg/dl)
 from various treatment groups



N=10 Five month old BWF1 mice were treated with protein for 8 weeks i.p.
 The hBCMA-300 stands for hBCMA-fc 300 µg/mouse (12mg/kg)

FIG. 34

Analysis of antibodies to dsDNA from the peripheral blood
from various treatment groups of BWF1 at day 0, 30, 60, and 90.

MEAN anti-dsDNA isotypes in U/ml

Group #	Day 0		Day 30		Day 60		Day 90	
	IgG	IgM	IgG	IgM	IgG	IgM	IgG	IgM
hBCMA-300	179	560	163	371	150	706	171	841
hBCMA-100	150	430	259	718	171	822	339	1031
hBCMA-30	377	592	297	458	401	664	424	601
FC.	149	371	234	283	384	331	432	351
PBS	308	292	439	311	247	576	720	467

Standard Deviation of the above means

Group #	Day 0		Day 30		Day 60		Day 90	
	IgG	IgM	IgG	IgM	IgG	IgM	IgG	IgM
hBCMA-300	104	303	116	211	62	518	62	734
hBCMA-100	109	262	306	461	212	758	371	1225
hBCMA-30	363	455	281	430	305	606	421	400
FC.	68	160	150	93	391	151	233	237
PBS	311	73	474	152	247	370	870	327

FIG. 35

Evaluation of B cell numbers at treatment day 60 from
the 12mg/kg (30 ug), 4mg/kg (100ug), and 1.3mg/kg (300 ug) dose of
hBCMA-Fc groups along with the Fc and PBS control groups.

hBCMA-fc-300				hBCMA-100				hBCMA-FC-30			
Mouse#	%CD4	%CD8	%B220	%CD4	%CD8	%B220		%CD4	%CD8	%B220	
1.0	16.3	11.0	16.4	26.1	14.9	10.1	5.0	9.0	2.5	6.9	10.3
2.0	24.1	11.1	11.6	21.1	11.3	10.6	6.0	10.0	13.2	5.2	23.4
3.0	18.2	7.4	9.9	24.6	13.3	8.3	7.0	11.0	15.9	6.4	29.2
4.0	25.4	13.3	13.1	20.0	11.3	13.4	8.0	12.0	14.8	7.6	31.5
x	21.0	10.7	12.8	23.0	12.7	10.6	x	x	11.6	6.5	23.6
sd	4.4	2.4	2.8	2.9	1.7	2.1	sd	sd	6.2	1.0	9.5
Fc				PBS							
33.0	7.0	8.1	25.4	16.9	8.3	15.5	37.0				
34.0	10.7	4.9	15.3	19.1	12.1	19.5	38.0				
35.0	18.9	9.3	21.0	7.1	3.4	17.5	39.0				
36.0	20.1	11.1	21.0	19.9	11.4	26.5	40.0				
x	14.2	8.4	20.7	15.8	8.8	19.8	x				
sd	6.4	2.6	4.1	5.9	4.0	4.8	sd				



FIG. 36

Specific APRIL binding to Human Cell lines determined by FACS analysis

APRIL binding

HT 29 Colon adenocarcinoma	+	+	+
NCI 460 Lung carcinoma	+	+	+
PC3 Prostate adenocarcinoma	+		+
C6 Glial carcinoma	+		+
Raji Burkitt lymphoma	+	+	+
A20 Mouse B cell lymphoma	+	+	+
U266BI Myeloma	+	+	+
A435 Epidermoid carcinoma	-		-
A469 Kidney carcinoma	-		-
MDA-231 breast adenocarcinoma	-		-

APPROVED	D.C. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		



FIG. 37

Effect of APRIL, BCMA-Fc and TACI-Fc truncated on U266BI cell proliferation






FIG. 38
 APRIL and AGP3 stimulates and BCMA-Fc
 inhibits B lymphoma cell proliferation






FIG. 39

Effects of BCMA & hTACI on the Growth of A20 in Balb/c Mice







FIG. 40
 EFFECT OF HUMAN BCMA-Fc AGAINST HT-29 SC TUMOR GROWTH
 Rx: IP, Q2D, day 0



* Linear growth ANOVA with Dunnett's correction for multiple testing (n=10/group)

FIG. 41
 EFFECT OF MURINE BCMA-Fc AGAINST HT-29 SC TUMOR GROWTH
 Rx: IP, Q2D, day 0

